Business · 22/07/1994Updated: 10/16/2026 · 1 min read
Determination of Regulatory Review Period for Purposes of Patent Extension; CattlystRegister 50 Type A Medicated Article
Summary
The Food and Drug Administration (FDA) has determined the regulatory review period for Cattlyst 50 Type A Medicated Article and published a notice as required by law.
Original source language: Federal Register — Health and Human ServicesOpen original release →